PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
|Articles|March 22, 2012
Gateway 2012: Veltek Associates, Inc.
Advertisement
Veltek Associates, Inc.
Company Profile
Veltek Associates, Inc. (VAI) is an EPA and FDA registered manufacturing facility. We focus on identification and control of contamination in classified areas. We produce a complete range of sterile pharmaceutical grade disinfectants, sporicides, lubricants, and buffer solutions; Asepti-Cleanse sterile IPA/ hand sanitizer hands-free dispensers; Environmental Monitoring Systems; Core2Clean Spray/Mop/Fog Systems.
The patented SimpleMIX® System is designed for the mixing of sterile disinfectants/sporicides in a sealed multi-chamber container eliminating concerns over handling and improper mixing of chemicals. Just push the internal cap and the two solutions instantly mix together. Visit us at InterPhex booth # 2508 to see all VAI’s product offerings.
Advertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
Advertisement
Advertisement